Apogee Therapeutics reported positive Phase 2 maintenance data for its moderate-to-severe eczema drug candidate on Monday. The company said its treatment could offer more convenient dosing compared to standard treatments currently available in the market.
The results position Apogee's candidate as a potential competitor to established eczema treatments like Dupixent and Ebglyss. Eczema, also known as atopic dermatitis, affects millions of patients worldwide and represents a significant pharmaceutical market opportunity for effective treatments.